Luxturna (voretigene neparvovec-rzyl) is a gene therapy drug approved by the FDA for the treatment of biallelic RPE65 mutation-associated retinal dystrophy. This condition is a rare genetic disorder that leads to progressive vision loss and ultimately, blindness. Luxturna works by delivering a normal copy of the RPE65 gene directly to retinal cells, thereby restoring vision.
